CCM
ALNY icon

Cinctive Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cinctive Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,300
Closed -$2.02M – 377
2024
Q2 		$2.02M Buy
+8,300
New +$1.31M 0.1% 254

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cinctive Capital Management's ALNY Position: Q2 2026 in Review

Cinctive Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 3,305 shares worth $995K. The stake represents 0.04% of the portfolio and ranks #326 among its holdings. This is a return to the name: Cinctive Capital Management previously reported a position in ALNY as recently as Q2 2025.

Cinctive Capital Management first reported a position in ALNY in Q4 2020 and has held it in 8 quarters since. The position peaked at $7.46M in Q2 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cinctive Capital Management held 3,305 shares of Alnylam Pharmaceuticals worth $995K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Cinctive Capital Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.04% of Cinctive Capital Management's portfolio in Q2 2026, its #326 holding.
  • Cinctive Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
  • Cinctive Capital Management's Alnylam Pharmaceuticals position peaked at $7.46M in Q2 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.